Idiosyncratic drug hepatotoxicity
The DOI matches its Crossref record; 154 of the 155 references it cites were found in a registry or an index.
Abstract
The occurrence of idiosyncratic drug hepatotoxicity is a major problem in all phases of clinical drug development and the most frequent cause of post-marketing warnings and withdrawals. This review examines the clinical signatures of this problem, signals predictive of its occurrence (particularly of more frequent, reversible, low-grade injury) and the role of monitoring in prevention by examining several recent examples (for example, troglitazone). In addition, the failure of preclinical toxicology to predict idiosyncratic reactions, and what can be done to improve this problem, is discussed. Finally, our current understanding of the pathophysiology of experimental drug hepatotoxicity is examined, focusing on acetaminophen, particularly with respect to the role of the innate immune system and control of cell-death pathways, which might provide targets for exploration and identification of risk factors and mechanisms in humans.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The current drug development process suffers from a high failure rate during clinical trials, which is partly due to inadequacy of animal models to accurately predict the toxic side-effects of drugs in humans [1,2].”
From A liver-on-a-chip platform with bioprinted hepatic spheroids (2016) · cites this paper as [2]
In the citing paper
“Drug-induced liver injury (DILI) is a common adverse drug reaction (ADR), and it can lead to liver failure and even death.[1][2][3]”
From Incidence and Etiology of Drug-Induced Liver Injury in Mainland China (2019) · cites this paper as [1]
Citations
Cites
A method for estimating the probability of adverse drug reactions
Naranjo, C. A., Busto, U., Sellers, E. M., Sandor, P., Ruiz, I., Roberts, E. A., Janecek, E., Domecq, C., & Greenblatt, D. J. (1981) · Clinical Pharmacology and Therapeutics · doi:10.1038/clpt.1981.154 · Cited by 11,914
Tolerance, Danger, and the Extended Family
Matzinger, P. (1994) · Annual Review of Immunology · doi:10.1146/annurev.iy.12.040194.005015 · Cited by 4,820
Schwartz, G. G. (2001) · JAMA · doi:10.1001/jama.285.13.1711 · Cited by 2,499
Ostapowicz, G., Fontana, R. J., Schiødt, F. V., Larson, A., Davern, T. J., Han, S. H. B., McCashland, T. M., Shakil, A. O., Hay, J. E., Hynan, L., et al. (2002) · Annals of Internal Medicine · doi:10.7326/0003-4819-137-12-200212170-00007 · Cited by 2,227
Concordance of the toxicity of pharmaceuticals in humans and in animals
Olson, H., Betton, G., Robinson, D., Thomas, K., Monro, A., Kolaja, G., Lilly, P., Sanders, J., Sipes, G., Bracken, W., et al. (2000) · Regulatory Toxicology and Pharmacology · doi:10.1006/rtph.2000.1399 · Cited by 2,050
Danan, G., & Benichou, C. (1993) · Journal of Clinical Epidemiology · doi:10.1016/0895-4356(93)90101-6 · Cited by 1,481
ACETAMINOPHEN-INDUCED HEPATIC NECROSIS. II. ROLE OF COVALENT BINDING IN VIVO
Jollow, D. J., Mitchell, J. R., Potter, W. Z., Davis, D. C., Gillette, J. R., & Brodie, B. B. (1973) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)29664-1 · Cited by 1,204
Acetaminophen-induced Hepatic Necrosis
Jollow, D. J., Thorgeirsson, S. S., Potter, W. Z., Hashimoto, M., & Mitchell, J. R. (1974) · Pharmacology · doi:10.1159/000136547 · Cited by 1,092
ANDRADE, R., LUCENA, M., FERNANDEZ, M., PELAEZ, G., PACHKORIA, K., GARCIARUIZ, E., GARCIAMUNOZ, B., GONZALEZGRANDE, R., PIZARRO, A., & DURAN, J. (2005) · Gastroenterology · doi:10.1016/j.gastro.2005.05.006 · Cited by 856
Hepatotoxic Effects of Tacrine Administration in Patients With Alzheimer's Disease
Watkins, P. B. (1994) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1994.03510370044030 · Cited by 829
Research works printed but not linked: 3
- Nelson, S. D. & Bruschi, S. A. in Drug-Induced Liver Disease (eds Kaplowitz, N. & DeLeve, L.) 287–325 (Marcel Dekker, New York, 2003).
- Chien, J. Y., Thummel, K. E. & Slattery, J. T. Pharmakinetic consequence of induction of CYP2E1 by ligand stabilization. Drug Metab. Dispos. 25, 1165–1175 (1997).
- Liu, Z. -X. & Kaplowitz, N. in Clinics in Liver Disease 6, 467–486 (Elsevier, 2002).
Cited by
Items 101–200 of 999
Assessment of Emerging Biomarkers of Liver Injury in Human Subjects
Schomaker, S., Warner, R., Bock, J., Johnson, K., Potter, D., Van Winkle, J., & Aubrecht, J. (2013) · Toxicological Sciences · doi:10.1093/toxsci/kft009 · Cited by 149
Hepatotoxicity Observed in Clinical Trials of Aplaviroc (GW873140)
Nichols, W. G., Steel, H. M., Bonny, T., Adkison, K. K., Curtis, L., Millard, J., Kabeya, K., & Clumeck, N. (2007) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00821-07 · Cited by 149
Pharmacogenetics of drug‐induced liver injury†
Russmann, S., Jetter, A., & Kullak‐Ublick, G. A. (2010) · Hepatology · doi:10.1002/hep.23720 · Cited by 147
Kizawa, H., Nagao, E., Shimamura, M., Zhang, G., & Torii, H. (2017) · Biochemistry and Biophysics Reports · doi:10.1016/j.bbrep.2017.04.004 · Cited by 143
Donaldson, P. T., Daly, A. K., Henderson, J., Graham, J., Pirmohamed, M., Bernal, W. E., Day, C. P., & Aithal, G. P. (2010) · Journal of Hepatology · doi:10.1016/j.jhep.2010.05.033 · Cited by 145
Reactive Metabolites: Current and Emerging Risk and Hazard Assessments
Thompson, R. A., Isin, E. M., Ogese, M. O., Mettetal, J. T., & Williams, D. P. (2016) · Chemical Research in Toxicology · doi:10.1021/acs.chemrestox.5b00410 · Cited by 140
Computational Models for Human and Animal Hepatotoxicity with a Global Application Scope
Mulliner, D., Schmidt, F., Stolte, M., Spirkl, H.-P., Czich, A., & Amberg, A. (2016) · Chemical Research in Toxicology · doi:10.1021/acs.chemrestox.5b00465 · Cited by 140
Thakkar, S., Li, T., Liu, Z., Wu, L., Roberts, R., & Tong, W. (2020) · Drug Discovery Today · doi:10.1016/j.drudis.2019.09.022 · Cited by 140
Smith, D. A., & Obach, R. S. (2009) · Chemical Research in Toxicology · doi:10.1021/tx800415j · Cited by 138
Hepatoprotective Effects of Mushrooms
Soares, A. A., de Sá‐Nakanishi, A. B., Bracht, A., Costa, S. D., Koehnlein, E. A., de Souza, C. D. F. D. O. B. A., & Peralta, R. M. (2013) · Molecules · doi:10.3390/molecules18077609 · Cited by 140
Torres, S., Baulies, A., Insausti-Urkia, N., Alarcón-Vila, C., Fucho, R., Solsona-Vilarrasa, E., Núñez, S., Robles, D., Ribas, V., Wakefield, L., et al. (2019) · Gastroenterology · doi:10.1053/j.gastro.2019.04.023 · Cited by 137
Self-citationInflammatory Stress and Idiosyncratic Hepatotoxicity: Hints from Animal Models
Deng, X., Luyendyk, J. P., Ganey, P. E., & Roth, R. A. (2009) · Pharmacological Reviews · doi:10.1124/pr.109.001727 · Cited by 154
Cosgrove, B. D., King, B. M., Hasan, M. A., Alexopoulos, L. G., Farazi, P. A., Hendriks, B. S., Griffith, L. G., Sorger, P. K., Tidor, B., Xu, J. J., et al. (2009) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2009.04.002 · Cited by 136
Genetic association studies in drug-induced liver injury
Daly, A. K., & Day, C. P. (2012) · Drug Metabolism Reviews · doi:10.3109/03602532.2011.605790 · Cited by 136
Toward Predictive Models for Drug-Induced Liver Injury in Humans: Are we There Yet?
Chen, M., Bisgin, H., Tong, L., Hong, H., Fang, H., Borlak, J., & Tong, W. (2014) · Biomarkers in Medicine · doi:10.2217/bmm.13.146 · Cited by 136
Li, C. Y., Stevens, K. R., Schwartz, R. E., Alejandro, B. S., Huang, J. H., & Bhatia, S. N. (2014) · Tissue Engineering Part A · doi:10.1089/ten.tea.2013.0667 · Cited by 132
Models of Drug Induced Liver Injury (DILI)—Current Issues and Future Perspectives
Kuna, L., Bozic, I., Kizivat, T., Bojanic, K., Mrso, M., Kralj, E., Smolic, R., Wu, G. Y., & Smolic, M. (2018) · Current Drug Metabolism · doi:10.2174/1389200219666180523095355 · Cited by 127
Gap junction inhibition prevents drug-induced liver toxicity and fulminant hepatic failure
Patel, S. J., Milwid, J. M., King, K. R., Bohr, S., Iracheta‐Vellve, A., Li, M., Vitalo, A. G., Parekkadan, B., Jindal, R., & Yarmush, M. L. (2012) · Nature Biotechnology · doi:10.1038/nbt.2089 · Cited by 128
Fernandez-Checa, J. C., Bagnaninchi, P., Ye, H., Sancho-Bru, P., Falcon-Perez, J. M., Royo, F., Garcia-Ruiz, C., Konu, O., Miranda, J., Lunov, O., et al. (2021) · Journal of Hepatology · doi:10.1016/j.jhep.2021.06.021 · Cited by 126
A Predictive Ligand-Based Bayesian Model for Human Drug-Induced Liver Injury
Ekins, S., Williams, A. J., & Xu, J. J. (2010) · Drug Metabolism and Disposition · doi:10.1124/dmd.110.035113 · Cited by 122
Psychotropic drugs and liver disease: A critical review of pharmacokinetics and liver toxicity
Telles‐Correia, D., Barbosa, A., Cortez‐Pinto, H., Campos, C., Rocha, N. B. F., & Machado, S. E. D. C. (2017) · World Journal of Gastrointestinal Pharmacology and Therapeutics · doi:10.4292/wjgpt.v8.i1.26 · Cited by 145
In Vitro Evaluation of Potential Hepatotoxicity Induced by Drugs
Gomez-Lechon, M. J., Lahoz, A., Gombau, L., Castell, J. V., & Donato, M. T. (2010) · Current Pharmaceutical Design · doi:10.2174/138161210791208910 · Cited by 120
A high content screening assay to predict human drug-induced liver injury during drug discovery
Persson, M., Løye, A. F., Mow, T. J., & Hornberg, J. J. (2013) · Journal of Pharmacological and Toxicological Methods · doi:10.1016/j.vascn.2013.08.001 · Cited by 120
Role of innate immunity in acetaminophen-induced hepatotoxicity
Liu, Z.-X., & Kaplowitz, N. (2006) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425255.2.4.493 · Cited by 117
Self-citationDigital light processing (DLP)‐based (bio)printing strategies for tissue modeling and regeneration
Li, H., Dai, J., Wang, Z., Zheng, H., Li, W., Wang, M., & Cheng, F. (2022) · Aggregate · doi:10.1002/agt2.270 · Cited by 154
Microengineered Liver Tissues for Drug Testing
Khetani, S. R., Berger, D. R., Ballinger, K. R., Davidson, M. D., Lin, C., & Ware, B. R. (2015) · SLAS Technology · doi:10.1177/2211068214566939 · Cited by 116
“Of such toxicities, drug-induced liver injury (DILI) is the most common cause of acute liver failures in the United States alone and is a leading cause of both the prelaunch and postmarket attrition of pharmaceuticals.(4) For instance, DILI accounts for ~40% of the drugs that fail during clinical trials and has been l…”
Background(+)-Clausenamide protects against drug-induced liver injury by inhibiting hepatocyte ferroptosis
Wang, M., Liu, C., Wang, T., Yu, H.-M., Ouyang, S., Wu, Y., Gong, H., Ma, X., Jiao, G., Fu, L., et al. (2020) · Cell Death and Disease · doi:10.1038/s41419-020-02961-5 · Cited by 122
Signal Transduction Pathways Involved in Drug-Induced Liver Injury
Han, D., Shinohara, M., Ybanez, M. D., Saberi, B., & Kaplowitz, N. (2009) · Handbook of experimental pharmacology · doi:10.1007/978-3-642-00663-0_10 · Cited by 121
Self-citationLucena, I. M., García-Martín, E., Andrade, R. J., Martínez, C., Stephens, C., Ruiz, J. D., Ulzurrun, E., Fernandez, C. M., Romero-Gomez, M., Castiella, A., et al. (2010) · Hepatology · doi:10.1002/hep.23668 · Cited by 115
Acetaminophen toxicity: Changing perceptions on a social/medical issue
Lee, W. M. (2007) · Hepatology · doi:10.1002/hep.21926 · Cited by 115
Shinohara, M., Ybanez, M. D., Win, S., Than, T. A., Jain, S., Gaarde, W. A., Han, D., & Kaplowitz, N. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.054999 · Cited by 114
Self-citationUsing controlled clinical trials to learn more about acute drug-induced liver injury
Watkins, P. B., Seligman, P. J., Pears, J. S., Avigan, M. I., & Senior, J. R. (2008) · Hepatology · doi:10.1002/hep.22633 · Cited by 115
Shaw, P. J., Ganey, P. E., & Roth, R. A. (2010) · Toxicological Sciences · doi:10.1093/toxsci/kfq168 · Cited by 123
Au, J. S., Navarro, V. J., & Rossi, S. (2011) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2011.04674.x · Cited by 112
Murata, D., Arai, K., & Nakayama, K. (2020) · Advanced Healthcare Materials · doi:10.1002/adhm.201901831 · Cited by 115
Immune-Mediated Adverse Drug Reactions
Uetrecht, J. (2009) · Chemical Research in Toxicology · doi:10.1021/tx800389u · Cited by 110
Lu, Y.-C., Song, W., An, D., Kim, B. J., Schwartz, R., Wu, M., & Ma, M. (2015) · Journal of Materials Chemistry B · doi:10.1039/c4tb01735h · Cited by 107
Evaluation of Serum Bile Acid Profiles as Biomarkers of Liver Injury in Rodents
Luo, L., Schomaker, S., Houle, C., Aubrecht, J., & Colangelo, J. L. (2014) · Toxicological Sciences · doi:10.1093/toxsci/kft221 · Cited by 108
The liver–gut microbiota axis modulates hepatotoxicity of tacrine in the rat
Yip, L. Y., Aw, C. C., Lee, S. H., Hong, Y., Ku, H. C., Xu, W. H., Chan, M. X. J., Cheong, E. J. Y., Chng, K. R., Ng, A. H. Q., et al. (2017) · Hepatology · doi:10.1002/hep.29327 · Cited by 115
Evaluation of Drug-Induced Serious Hepatotoxicity (eDISH)
Watkins, P. B., Desai, M. G., Berkowitz, S. D., Peters, G. R., Horsmans, Y., Larrey, D. G., & Maddrey, W. C. (2011) · Drug Safety · doi:10.2165/11586600-000000000-00000 · Cited by 109
Sison-Young, R. L., Lauschke, V. M., Johann, E., Alexandre, E., Antherieu, S., Aerts, H., Gerets, H. H. J., Labbe, G., Hoët, D., Dorau, M., et al. (2017) · Archives of Toxicology · doi:10.1007/s00204-016-1745-4 · Cited by 104
Pharmacological properties of baicalin on liver diseases: a narrative review
Yang, J., Li, M., Zhang, C., & Liu, D. (2021) · Pharmacological Reports · doi:10.1007/s43440-021-00227-1 · Cited by 116
ResNet18DNN: prediction approach of drug-induced liver injury by deep neural network with ResNet18
Chen, Z., Jiang, Y., Zhang, X., Zheng, R., Qiu, R., Sun, Y., Zhao, C., & Shang, H. (2022) · Briefings in Bioinformatics · doi:10.1093/bib/bbab503 · Cited by 102
Three-Dimensional HepaRG Model As An Attractive Tool for Toxicity Testing
Leite, S. B., Wilk-Zasadna, I., Zaldivar, J. M., Airola, E., Reis-Fernandes, M. A., Mennecozzi, M., Guguen-Guillouzo, C., Chesne, C., Guillou, C., Alves, P. M., et al. (2012) · Toxicological Sciences · doi:10.1093/toxsci/kfs232 · Cited by 103
ADDME – Avoiding Drug Development Mistakes Early: central nervous system drug discovery perspective
Tsaioun, K., Bottlaender, M., Mabondzo, A., & the Alzheimer's Drug Discovery Foundation (2009) · BMC Neurology · doi:10.1186/1471-2377-9-s1-s1 · Cited by 103
Acetaminophen and pregnancy: short- and long-term consequences for mother and child
Thiele, K., Keßler, T., Arck, P., Erhardt, A., & Tiegs, G. (2013) · Journal of Reproductive Immunology · doi:10.1016/j.jri.2012.10.014 · Cited by 113
Eighteen cases of liver injury following ingestion of Polygonum multiflorum
Dong, H., Slain, D., Cheng, J., Ma, W., & Liang, W. (2014) · Complementary Therapies in Medicine · doi:10.1016/j.ctim.2013.12.008 · Cited by 98
Harrill, A. H., Ross, P. K., Gatti, D. M., Threadgill, D. W., & Rusyn, I. (2009) · Toxicological Sciences · doi:10.1093/toxsci/kfp096 · Cited by 103
A Model to predict severity of drug‐induced liver injury in humans
Chen, M., Borlak, J., & Tong, W. (2016) · Hepatology · doi:10.1002/hep.28678 · Cited by 104
Xuan, J., Chen, S., Ning, B., Tolleson, W. H., & Guo, L. (2016) · Chemico-Biological Interactions · doi:10.1016/j.cbi.2015.10.009 · Cited by 103
Acetaminophen‐related acute liver failure in the United States
Lee, W. M. (2008) · Hepatology Research · doi:10.1111/j.1872-034x.2008.00419.x · Cited by 102
In silico Prediction of Drug Induced Liver Toxicity Using Substructure Pattern Recognition Method
Zhang, C., Cheng, F., Li, W., Liu, G., Lee, P. W., & Tang, Y. (2016) · Molecular Informatics · doi:10.1002/minf.201500055 · Cited by 111
Hill, A., Mesens, N., Steemans, M., Xu, J. J., & Aleo, M. D. (2012) · Drug Metabolism Reviews · doi:10.3109/03602532.2011.645578 · Cited by 111
Rose, K. A., Holman, N. S., Green, A. M., Andersen, M. E., & LeCluyse, E. L. (2016) · Journal of Pharmaceutical Sciences · doi:10.1016/s0022-3549(15)00192-6 · Cited by 99
Drug induced liver injury and its relationship to autoimmune hepatitis
Weiler-Normann, C., & Schramm, C. (2011) · Journal of Hepatology · doi:10.1016/j.jhep.2011.02.024 · Cited by 92
Joseph, P. (2017) · Food and Chemical Toxicology · doi:10.1016/j.fct.2017.07.031 · Cited by 111
Progress in the treatment of drug-induced liver injury with natural products
Sun, Y., Zhang, Y., Xie, L., Rong, F., Zhu, X.-Y., Xie, J., Zhou, H., & Xu, T. (2022) · Pharmacological Research · doi:10.1016/j.phrs.2022.106361 · Cited by 112
Approach to a Patient with Elevated Serum Alkaline Phosphatase
Siddique, A., & Kowdley, K. V. (2012) · Clinics in Liver Disease · doi:10.1016/j.cld.2012.03.012 · Cited by 98
Lassila, T., Hokkanen, J., Aatsinki, S., Mattila, S., Turpeinen, M., & Tolonen, A. (2015) · Chemical Research in Toxicology · doi:10.1021/acs.chemrestox.5b00315 · Cited by 108
Liu, Z., Shi, Q., Ding, D., Kelly, R., Fang, H., & Tong, W. (2011) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1002310 · Cited by 96
Etiologies of acute liver failure
Lee, W. M., & Seremba, E. (2008) · Current Opinion in Critical Care · doi:10.1097/mcc.0b013e3282f6a420 · Cited by 96
Soglia, J. R., Contillo, L. G., Kalgutkar, A. S. S., Zhao, S. X., Hop, C. E. C. A., Boyd, J. G., & Cole, M. J. (2006) · Chemical Research in Toxicology · doi:10.1021/tx050303c · Cited by 96
Toxicological Significance of Mechanism-Based Inactivation of Cytochrome P450 Enzymes by Drugs
Masubuchi, Y., & Horie, T. (2007) · Critical Reviews in Toxicology · doi:10.1080/10408440701215233 · Cited by 95
Li, T., Tong, W., Roberts, R. A., Liu, Z., & Thakkar, S. (2020) · Chemical Research in Toxicology · doi:10.1021/acs.chemrestox.0c00374 · Cited by 108
Drug-Induced Liver Injury: Insights from Genetic Studies
Andrade, R. J., Robles, M., Ulzurrun, E., & Lucena, M. I. (2009) · Pharmacogenomics · doi:10.2217/pgs.09.111 · Cited by 94
Garside, H., Marcoe, K. F., Chesnut-Speelman, J., Foster, A. J., Muthas, D., Gerry Kenna, J., Warrior, U., Bowes, J., & Baumgartner, J. (2014) · Toxicology in Vitro · doi:10.1016/j.tiv.2013.10.015 · Cited by 93
Zuppinger, C. (2015) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2015.11.036 · Cited by 105
Christoffersson, J., Aronsson, C., Jury, M., Selegård, R., Aili, D., & Mandenius, C.-F. (2018) · Biofabrication · doi:10.1088/1758-5090/aaf657 · Cited by 92
Davern, T. J. (2012) · Clinics in Liver Disease · doi:10.1016/j.cld.2012.03.002 · Cited by 104
Olanow, C. W., & Watkins, P. B. (2007) · Clinical Neuropharmacology · doi:10.1097/wnf.0b013e318038d2b6 · Cited by 93
Krauskopf, J., Caiment, F., Claessen, S. M., Johnson, K. J., Warner, R. L., Schomaker, S. J., Burt, D. A., Aubrecht, J., & Kleinjans, J. C. (2015) · Toxicological Sciences · doi:10.1093/toxsci/kfu232 · Cited by 93
Biomarkers for drug-induced liver injury
Shi, Q., Hong, H., Senior, J., & Tong, W. (2010) · Expert Review of Gastroenterology & Hepatology · doi:10.1586/egh.10.8 · Cited by 89
Liu, R., Yu, X., & Wallqvist, A. (2015) · Journal of Cheminformatics · doi:10.1186/s13321-015-0053-y · Cited by 92
“For example, ADRs may be over-reported for a new or “untrusted” drug and underreported for a “trusted” drug.”
BackgroundInfluentialHuang, Y. X., Qi, Y., Zhan, C., Zeng, F., & Wu, S. (2019) · Analytical Chemistry · doi:10.1021/acs.analchem.9b00107 · Cited by 93
Engineered Liver Platforms for Different Phases of Drug Development
Ware, B. R., & Khetani, S. R. (2017) · Trends in Biotechnology · doi:10.1016/j.tibtech.2016.08.001 · Cited by 90
“Drug-induced liver injury (DILI) is a leading cause of drug attrition in preclinical and clinical testing, black-box warnings on marketed drugs, the withdrawal of previously approved drugs, and acute liver failures [4].”
BackgroundAn integrative machine learning approach for prediction of toxicity-related drug safety
Lysenko, A., Sharma, A., Boroevich, K. A., & Tsunoda, T. (2018) · Life Science Alliance · doi:10.26508/lsa.201800098 · Cited by 88
Avior, Y., Levy, G., Zimerman, M., Kitsberg, D., Schwartz, R., Sadeh, R., Moussaieff, A., Cohen, M., Itskovitz‐Eldor, J., & Nahmias, Y. (2015) · Hepatology · doi:10.1002/hep.27803 · Cited by 88
“Because of these metabolic functions, the organ is particularly sensitive to drug-induced liver injury (DILI), a leading cause of acute liver failure and postmarket drug withdrawals.(2) Therefore, liver toxicity and drug”
BackgroundThe Importance of Patient-Specific Factors for Hepatic Drug Response and Toxicity
Lauschke, V., & Ingelman-Sundberg, M. (2016) · International Journal of Molecular Sciences · doi:10.3390/ijms17101714 · Cited by 88
Chen, Y., Liu, K., Zhang, J., Hai, Y., Wang, P., Wang, H., Liu, Q., Wong, C. C. L., Yao, J., Gao, Y., et al. (2020) · Hepatology · doi:10.1002/hep.31116 · Cited by 88
Bourdi, M., Eiras, D. P., Holt, M. R., Webster, M. R., Reilly, T. P., Welch, K. D., & Pohl, L. R. (2007) · Chemical Research in Toxicology · doi:10.1021/tx060228l · Cited by 92
Three-Dimensional Cell Cultures in Toxicology
Pampaloni, F., & Stelzer, E. H. (2009) · Biotechnology and Genetic Engineering Reviews · doi:10.5661/bger-26-117 · Cited by 88
Sulforaphane protects against acetaminophen-induced hepatotoxicity
Noh, J., Kim, Y., Hwang, J. H., Choi, D., Kim, K., Oh, W. K., & Lee, C. (2015) · Food and Chemical Toxicology · doi:10.1016/j.fct.2015.03.020 · Cited by 92
Understanding the role of reactive metabolites in drug-induced hepatotoxicity: state of the science
Antoine, D. J., Williams, D. P., & Park, B. K. (2008) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425255.4.11.1415 · Cited by 87
Multiple effects of acetaminophen and p38 inhibitors: Towards pathway toxicology
Xu, J. J., Hendriks, B. S., Zhao, J., & de Graaf, D. (2008) · FEBS Letters · doi:10.1016/j.febslet.2008.01.063 · Cited by 90
Direct Reprogramming of Human Fibroblasts to Hepatocyte-Like Cells by Synthetic Modified mRNAs
Simeonov, K. P., & Uppal, H. (2014) · PLoS ONE · doi:10.1371/journal.pone.0100134 · Cited by 86
Usta, O. B., McCarty, W. J., Bale, S., Hegde, M., Jindal, R., Bhushan, A., Golberg, I., & Yarmush, M. L. (2015) · TECHNOLOGY · doi:10.1142/s2339547815300012 · Cited by 85
Interspecies differences in acetaminophen sensitivity of human, rat, and mouse primary hepatocytes
Jemnitz, K., Veres, Z., Monostory, K., Kob́ori, L., & Vereczkey, L. (2008) · Toxicology in Vitro · doi:10.1016/j.tiv.2008.02.001 · Cited by 99
Takakusa, H., Masumoto, H., Yukinaga, H., Makino, C., Nakayama, S., Okazaki, O., & Sudo, K. (2008) · Drug Metabolism and Disposition · doi:10.1124/dmd.108.021725 · Cited by 85
Antidepressant-lnduced Liver Injury
DeSanty, K. P., & Amabile, C. M. (2007) · Annals of Pharmacotherapy · doi:10.1345/aph.1k114 · Cited by 84
Alsherbiny, M. A., Abd-Elsalam, W. H., Badawy, S. A. E., Taher, E. S., Farès, M., Torres, A. M., Chang, D., & Li, C. G. (2018) · Food and Chemical Toxicology · doi:10.1016/j.fct.2018.10.048 · Cited by 88
In silico models for drug-induced liver injury – current status
Przybylak, K. R., & Cronin, M. T. (2012) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425255.2012.648613 · Cited by 82
Ennulat, D., Magid-Slav, M., Rehm, S., & Tatsuoka, K. S. (2010) · Toxicological Sciences · doi:10.1093/toxsci/kfq144 · Cited by 95
Mechanisms of Pathogenesis in Drug Hepatotoxicity Putting the Stress on Mitochondria
Jones, D. P., Lemasters, J. J., Han, D., Boelsterli, U. A., & Kaplowitz, N. (2010) · Molecular Interventions · doi:10.1124/mi.10.2.7 · Cited by 93
Self-citationPotential protective effect of honey against paracetamol-induced hepatotoxicity.
Galal, R. M., Zaki, H. F., El-Nasr, M. M. S., & Agha, A. M. (2012) · PubMed · Cited by 81
Testing for drug hypersensitivity syndromes.
Rive, C. M., Bourke, J., & Phillips, E. J. (2013) · Europe PMC (PubMed Central) · Cited by 100
Baldo, B. A., & Pham, N. H. (2013) · Cancer and Metastasis Reviews · doi:10.1007/s10555-013-9447-3 · Cited by 95
Drug-Induced Liver Injury: Past, Present and Future
Daly, A. K. (2010) · Pharmacogenomics · doi:10.2217/pgs.10.24 · Cited by 80
Characteristics of liver injury in drug-induced systemic hypersensitivity reactions
Lee, T., Lee, Y. S., Yoon, S., Kim, S., Bae, Y., Kwon, H., Cho, Y. S., Moon, H., & Kim, T. (2013) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2013.03.024 · Cited by 80
Animal models of idiosyncratic drug-induced liver injury—Current status
Roth, R. A., & Ganey, P. E. (2011) · Critical Reviews in Toxicology · doi:10.3109/10408444.2011.575765 · Cited by 80
Vunjak-Novakovic, G., Bhatia, S., Chen, C., & Hirschi, K. (2013) · Stem Cell Research & Therapy · doi:10.1186/scrt369 · Cited by 80
Metadata
- Authors
- Kaplowitz, N.
- Affiliations
- University of Southern California (US)
- Corresponding author
- Kaplowitz, Neil
- ORCID
- Kaplowitz, Neil
- Venue
- Nature Reviews Drug Discovery
- Published
- 2005-06
- Volume
- 4
- Issue
- 6
- Pages
- 489-499
- ISSN
- 1474-1776 (ISSN-L)
- 1474-1784
- OpenAlex
- W2017783406
- Cited by
- 1,054
- References
- 155
- Citations by year
- 2026: 29 · 2025: 35 · 2024: 35 · 2023: 44 · 2022: 31 · 2021: 49 · 2020: 45 · 2019: 48 · 2018: 54 · 2017: 66 · 2016: 72 · 2015: 55 · 2014: 64 · 2013: 57 · 2012: 52
- FWCI
- 5.66
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Reviews Drug Discovery (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health
- Topics
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Drug-Induced Hepatotoxicity and Protection
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Toxicology › Pharmacovigilance and Adverse Drug Reactions
- Health Sciences › Medicine › Pharmacology (medical) › Drug-Induced Adverse Reactions
- Keywords
- drug-induced liver injury, troglitazone, preclinical toxicology, hepatotoxicity prediction, pharmacovigilance, acetaminophen hepatotoxicity, innate immune system, cell death pathways, drug withdrawal, post-marketing surveillance
- MeSH terms
- Animals, Pharmaceutical Preparations, Humans, Liver, Liver Diseases, Chemical and Drug Induced Liver Injury, Drug-Related Side Effects and Adverse Reactions
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.